Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

1 Oct 2009

Abstract excerpt

There is an urgent need for Alzheimer's disease (AD) biomarkers-especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Proteomics Techniques and Applications
Share to Alzheimer's disease research and treatments
Share to S100 Proteins and Annexins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19906259
DOI: 10.1111/j.1749-6632.2009.05064.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's DiseasePMID 19906259Read ↗

Biomarkers for Alzheimer's disease.Semantic proximity Read ↗

Developing an international network for Alzheimer’s research: the Dominantly Inherited Alzheimer NetworkSemantic proximity Read ↗

Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformSemantic proximity Read ↗

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read ↗

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s diseaseSemantic proximity Read ↗

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer’s disease: sequence and timingSemantic proximity Read ↗

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's DiseaseSemantic proximity Read ↗

Potential Peripheral Biomarkers for the Diagnosis of Alzheimer′s DiseaseSemantic proximity Read ↗

High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity Read ↗

Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s diseaseSemantic proximity Read ↗

Emerging Biomarkers for Early Detection of Alzheimer’s Disease: A Systematic ReviewSemantic proximity Read ↗

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular eventsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.